CSFB Lowers Earnings Estimates for Merck
CSFB cut its earnings estimates and price target for Merck (MRK ) after the drug maker recalled its arthritis drug Vioxx. CSFB has an underperform rating on the stock.
To continue reading this article you must be a Bloomberg Professional Service Subscriber.
If you believe that you may have received this message in error please let us know.